Nyse rcus.

HAYWARD, Calif., February 09, 2023--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies ...Source. Headline. From laggards to leaders: Small caps on the rise (RCUS) marketbeat.com - November 27 at 8:45 AM. Brokerages Set Arcus Biosciences, Inc. (NYSE:RCUS) Price Target at $43.13. americanbankingnews.com - November 26 at 2:30 AM. Arcus Biosciences' Oncology Odyssey: The Domvanalimab Journey. seekingalpha.com - November 20 at 5:46 PM.Arcus Biosciences, Inc. SÀN CHỨNG KHOÁN / STOCK EXCHANGE NYSE (US). MÃ CHỨNG KHOÁN / TICKER RCUS. KỲ BÁO CÁO 2022. NGÀNH / INDUSTRY Biotechnology. LĨNH VỰC ...The RCUS shares have gain 14.30% over the last week, with a monthly amount glided 1.58%, and seem At the time of writing, Arcus Biosciences Inc [RCUS] stock is trading at $16.07, up 6.71%. It is a good measure of the stock's recent performance to check whether the stock's short-term value is rising or falling.

Pfizer, Inc.'s (NYSE:PFE) COVID-19 vaccine sales buoyed its quarter results and prompted the company to raise its guidance. ... Arcus Biosciences, Inc. (NYSE:RCUS) (after the close)FOSTER CITY, Calif., & HAYWARD, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) and Arcus Biosciences, Inc. (NYSE: RCUS) today announced positive results from the fourth interim analysis of the ARC-7 study in patients with first-line, metastatic non-small cell lung cancer (NSCLC) with PD-L1 tumor …HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that the ...

HAYWARD, Calif., December 09, 2022--Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that the ...Arcus Biosciences Stock Performance. NYSE RCUS opened at $13.87 on Thursday. Arcus Biosciences has a one year low of $12.95 and a one year high of $36.13. The firm’s fifty day moving average is $16.47 and its two-hundred day moving average is $18.74. The firm has a market cap of $1.04 billion, a PE ratio of -3.47 and a beta of 0.76.

RCUS Earnings Date and Information. Arcus Biosciences last announced its earnings data on November 7th, 2023. The reported ($0.94) EPS for the quarter, beating the consensus estimate of ($1.12) by $0.18. The business earned $32 million during the quarter, compared to analyst estimates of $27.57 million. Arcus Biosciences, Inc. (NYSE:RCUS) Q3 2023 Earnings Call Transcript November 8, 2023 Operator: Thank you and welcome to the call. Following prepared remarks from the Company, we will open the ...NYSE: Arcus Biosciences Inc (RCUS) = 14.62 USD. Provided by Alpha Vantage. Arcus Biosciences Inc stock (RCUS) in USD. 1 RCUS = 14.62 USD. 1 month. 6 months. 1 year. …Gilead Sciences, Inc. (Nasdaq: GILD) and Arcus Biosciences, Inc. (NYSE: RCUS) today announced positive results from the fourth interim analysis of the ARC-7 study in patients with first-line, metastatic non-small cell lung cancer (NSCLC) with PD-L1 tumor proportion score (TPS) ≥50% without epidermal growth factor receptor or anaplastic …Arcus Biosciences (RCUS). (Delayed Data from NYSE). $16.07 USD. 16.07. 801,268. +1.01 (6.71%). Updated Dec 1, 2023 04:00 PM ET. After-Market: $15.75 -0.32 (- ...

29 thg 8, 2023 ... (NYSE:RCUS) in Jan 2021 and then again in Jan 2022, pretty much with the same price at publication. That is to say, it was $38 in 2021, and ...

Dec 4, 2023 · – Phase 1b/2 clinical trial expected to begin enrolling patients before year-end 2023 – Exelixis, Inc. (NASDAQ:EXEL) and Arcus Biosciences (NYSE:RCUS) today announced that the companies have ...

– Phase 1b/2 clinical trial expected to begin enrolling patients before year-end 2023 – Exelixis, Inc. (NASDAQ:EXEL) and Arcus Biosciences (NYSE:RCUS) today announced that the companies have ...Arcus Biosciences Inc. analyst ratings, historical stock prices, earnings estimates & actuals. RCUS updated stock price target summary.HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies ...HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE: RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that the ...Gainers Applied Genetic Technologies (NASDAQ: AGTC) shares are trading higher after the company announced that it plans to release 12-month data for adult patients and low-dose pediatric patients ...Arcus Biosciences, Inc. (NYSE:RCUS – Get Free Report) has earned an average rating of “Moderate Buy” from the eight analysts that are covering the firm, MarketBeat reports. One investment analyst has rated the stock with a hold recommendation and seven have assigned a buy recommendation to the company. The average twelve-month target price among analysts […]

Arcus Biosciences, Inc. , an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that the Compensation Committee of the Company’s Board...FOSTER CITY, Calif., & HAYWARD, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) and Arcus Biosciences, Inc. (NYSE: RCUS) today announced that domvanalimab plus zimberelimab and chemotherapy showed encouraging overall response rate (ORR) and six-month progression-free survival (PFS) rate results …Arcus Biosciences, Inc. (NYSE:RCUS) is the most popular stock in this table. On the other hand Applied Molecular Transport Inc. (NASDAQ: AMTI ) is the least popular one with only 2 bullish hedge ...FOSTER CITY, Calif., & HAYWARD, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) and Arcus Biosciences, Inc. (NYSE: RCUS) today announced that the companies have expanded the previously announced research collaboration focused on oncology to include therapies for the treatment of inflammatory …FOSTER CITY, Calif., & HAYWARD, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) and Arcus Biosciences, Inc. (NYSE: RCUS) today announced that the companies have expanded the previously announced research collaboration focused on oncology to include therapies for the treatment of inflammatory …FOSTER CITY, Calif., & HAYWARD, Calif., June 03, 2023--Gilead Sciences, Inc. (Nasdaq: GILD) and Arcus Biosciences, Inc. (NYSE: RCUS) today announced updated results from an interim analysis of the ...The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. We have processed the filings of the more than 866 world-class investment firms that we track and now have access to the collective wisdom contained in […]

HAYWARD, Calif., May 08, 2023--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for ...HAYWARD, Calif., November 27, 2023--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination...

Arcus Biosciences Inc (NYSE: RCUS) argenx SE – ADR (NASDAQ: ARGX) Atea Pharmaceuticals Inc (NASDAQ: AVIR) BioVie Inc (NASDAQ: BIVI) C4 Therapeutics Inc (NASDAQ: CCCC)We would like to show you a description here but the site won’t allow us.RCUS 30-Year Financial Data The intrinsic value of RCUS Arcus Biosciences Inc is a clinical-stage biopharmaceutical company that focuses on developing immunotherapies for cancer treatment.Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, announced that its management team will participate in the following upcoming investor conferences in September:Shares of the cancer specialist Arcus Biosciences ( RCUS -1.07%) jumped by approximately 31% during the month of November, according to data from S&P Global Market Intelligence. The biotech's ...HAYWARD, Calif., November 27, 2023--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies ...The latest price target for Arcus Biosciences ( NYSE: RCUS) was reported by Cantor Fitzgerald on Thursday, September 7, 2023. The analyst firm set a price target for 46.00 expecting RCUS to rise ...Real time Arcus Biosciences (RCUS) stock price quote, stock graph, news & analysis.Nov 27, 2023 · Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that the Compensation Committee of the Company’s Board of Directors granted four new employees options to purchase a total of 12,600 shares of the Company’s common ... HAYWARD - Arcus Biosciences, Inc. (NYSE: RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced seven accepted abstracts at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, which will be held June 2-6, 2023.

Nov 22, 2023 · NYSE:RCUS opened at $13.80 on Wednesday. Arcus Biosciences, Inc. has a twelve month low of $12.95 and a twelve month high of $36.13. The stock’s 50-day simple moving average is $16.61 and its ...

Arcus Biosciences, Inc. (NYSE: RCUS) was in 27 hedge funds' portfolios at the end of March. The all time high for this statistic is 31. RCUS has experienced a decrease in enthusiasm from smart ...

Nov 9, 2023 · During the last session, Arcus Biosciences Inc (NYSE:RCUS)’s traded shares were 0.88 million, with the beta value of the company hitting 0.75. At the end of the trading day, the stock’s price was $16.01, reflecting an intraday loss of -2.67% or -$0.44. The 52-week high for the RCUS share is $36. FOSTER CITY, Calif. & HAYWARD, Calif., November 28, 2022--Gilead Sciences, Inc. (Nasdaq: GILD) and Arcus Biosciences (NYSE: RCUS) today announced a positive update from the fourth interim analysis ...Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, announced that its management team will participate in the following upcoming investor conferences in September: 2023 Wells Fargo Healthcare Conference Date: Wednesday, September 6 th , 2023 at 10:15 a.m. ET Location ...Arcus Biosciences Inc. analyst ratings, historical stock prices, earnings estimates & actuals. RCUS updated stock price target summary. TD Asset Management Inc raised its stake in shares of Arcus Biosciences, Inc. (NYSE:RCUS – Free Report) by 52.6% in the second quarter, according to its most recent 13F filing with the SEC.The ...29 thg 8, 2023 ... (NYSE:RCUS) in Jan 2021 and then again in Jan 2022, pretty much with the same price at publication. That is to say, it was $38 in 2021, and ...Recent SEC filings show the company has made significant investments in AlloVir Inc. NASDAQ: ALVR and Arcus Biosciences Inc. NYSE: RCUS. This is a common practice for large-cap biotech companies because it allows them to have access to and market the intellectual property of these companies as it expands their portfolio of drugs …RCUSNYSE See on Supercharts Overview News Ideas Financials Technicals Forecast RCUS chart Today 3.13% 5 days 8.30% 1 month −11.75% 6 months −18.14% Year to …Gilead Sciences Inc (NASDAQ: GILD) and Arcus Biosciences Inc (NYSE: RCUS) announced that domvanalimab plus zimberelimab and chemotherapy showed encouraging overall response rate (ORR) and six ...

Arcus Biosciences, Inc. (NYSE:RCUS – Get Free Report)’s share price fell 3.7% during mid-day trading on Friday . The stock traded as low as $14.45 and last traded at $14.50. 19,641 shares were ...HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that the ...RCUS 30-Year Financial Data. The intrinsic value of RCUS. Arcus Biosciences is a clinical-stage biopharmaceutical company that focuses on developing immunotherapies for the treatment of various ...– Phase 1b/2 clinical trial expected to begin enrolling patients before year-end 2023 – Exelixis, Inc. (NASDAQ:EXEL) and Arcus Biosciences (NYSE:RCUS) today announced that the companies have ...Instagram:https://instagram. best options alert servicesnowflake stoclbbh stockmovileye ... RCUS(RCUS)股票股价,股票实时行情,新闻,财报,美股实时交易数据,研究报告,评级,财务指标分析等与RCUS(RCUS) ... RCUS NYSE:RCUS Arcus Biosciences, I. 添加自选 在APP中查看.Arcus Biosciences, Inc. , an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that the Compensation Committee of the Company’s Board of... -September 09, 2022 at 04:07 pm- MarketScreener blue chip stock listjnj target stock price Gilead Sciences Inc (NASDAQ: GILD) and Arcus Biosciences Inc (NYSE: RCUS) announced that domvanalimab plus zimberelimab and chemotherapy showed encouraging overall response rate ... najarian brothers cnbc Nov 10, 2023 · The following insider purchased RCUS shares in the last 24 months: Gilead Sciences, Inc. ($19,452,600.00). How much insider buying is happening at Arcus Biosciences? Insiders have purchased a total of 1,010,000 RCUS shares in the last 24 months for a total of $19,452,600.00 bought. ARCUS BIOSCIENCES (NYSE: RCUS.US) | Ticker Rank: 17965 (+70) | ☆ 3. 2023101222001120231013020000. After Hours (half-spread): 13 paź, 2:00 16.9250 +1.1050 (+ ...HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS) today announced that data from cohort A1 of the ongoing Phase 2 EDGE-Gastric study will be presented at the American Society ...